Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Common Equity (2016 - 2025)

Historic Common Equity for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to -$4.5 million.

  • Fennec Pharmaceuticals' Common Equity rose 1313.09% to -$4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.5 million, marking a year-over-year increase of 1313.09%. This contributed to the annual value of -$5.9 million for FY2024, which is 4947.51% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Common Equity stood at -$4.5 million, which was up 1313.09% from -$7.5 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Common Equity's 5-year high stood at $24.9 million during Q1 2021, with a 5-year trough of -$11.6 million in Q4 2023.
  • Its 5-year average for Common Equity is $2.3 million, with a median of -$2.0 million in 2022.
  • In the last 5 years, Fennec Pharmaceuticals' Common Equity surged by 24193.43% in 2023 and then crashed by 44996.32% in 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Common Equity (Quarter) stood at $19.0 million in 2021, then plummeted by 113.51% to -$2.6 million in 2022, then tumbled by 352.39% to -$11.6 million in 2023, then surged by 49.48% to -$5.9 million in 2024, then rose by 23.5% to -$4.5 million in 2025.
  • Its last three reported values are -$4.5 million in Q3 2025, -$7.5 million for Q2 2025, and -$5.9 million during Q1 2025.